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Aim. To study the effect of different antiplatelet regimens (APT) on the rate of postoperative TCD registered micro-embolic
signals (MES) following carotid endarterectomy (CEA).
Design. Prospective, randomised, double-blinded, pilot study.
Methods. The study group of 102 CEA patients (76 men, mean age 66.8 years) was randomised to routine Asasantin
(Dipyridamole 200 mg/Aspirin 25 mg) twice daily (group I; n¼ 39), Asasantin plus 75 mg Clopidogrel once daily (group II;
n¼ 33), or Asasantin plus Rheomacrodex (Dextran 40) 100 g/L iv; 500 ml (group III; n¼ 30). TCD monitoring of the
ipsilateral middle cerebral artery for the occurrence of MES was performed intra-operatively and during the second post-
operative hour following CEA. Primary endpoints were the rate of postoperative emboli and the occurrence of cerebrovascular
complications. Secondary endpoint was any adverse bleeding.
Results. There were no deaths or major strokes. We observed 2 intraoperative TIA’s (group II and III) and 1 postoperative
minor stroke (group I). In comparison with placebo, Clopidogrel or Rheomacrodex in addition to Asasantin produced no
significant reduction in the number of postoperative MES. There was no significant difference between the number of post-
operative MES and different antiplatelet regimens. The incidence of bleeding complications was not significantly different
between the 3 APT groups.
Conclusion. In the present study, we could not show a significant influence of different antiplatelet regimens on TCD
detected postoperative embolization following CEA.
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The in-hospital mortality of carotid endarterectomy
(CEA) is 0e2% and the occurrence of ipsilateral minor
or major stroke is reported 2e5%.1,2 Intraoperative
stroke, apparent on recovery from anaesthesia, has
been virtually abolished by introducing a policy of in-
traoperative transcranial Doppler (TCD) monitor-
ing.3,4 However, this policy showed little effect on
the prevention of early (<6 hours) postoperative
stroke due to thrombosis of the endarterectomised
zone, which continued to complicate 2.5% of
CEA’s.4e6 It is well known that platelets begin to
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of flow restoration7 but it is still unknown why this
becomes excessive in some patients, leading to new
postoperative cerebral deficits.
Several centres have shown that patients destined
to suffer an early postoperative stroke have a 1- to
2- hour period of increasing embolization before cere-
bral deficit becomes apparent.4,8e12 The prevailing
view is that, as the platelet thrombus accumulates,
small particles are shed into the carotid circulation
as micro-emboli. These micro-embolic signals (MES)
can be detected by postoperative TCD monitoring of
the ipsilateral middle cerebral artery (MCA). Overall,
about 50% of patients with CEA will have one or more
emboli detected in the postoperative period, but only
about 5% will progress to high grade sustained embo-
lization.4,5,13 Of these, 30% to 60% will progress toerved.
136 G. J. de Borst et al.thrombotic stroke.8,10 Except for a meticulous surgical
technique during endarterectomy the choice of anti-
platelet therapy might be a powerful instrument to
prevent these postoperative MES.14e16 It is important
to note that commonly used pretreatment regimens
with antiplatelet agents, in most cases aspirin, do
not abolish thrombo-embolization or embolic stroke
in the early postoperative period.17 Aspirin inhibits
only 1 of the several pathways of platelet activation,
and platelet activation through an aspirin insensitive
pathway may be more important in the occurrence
of thrombo-embolization.18 Dual therapy with aspirin
and Clopidogrel therefore may prove more effective
in reducing thrombo-embolic complications.15,19
Postoperative monitoring for MES is believed to be
a proper quantative diagnostic tool that helps in de-
ciding which patients could benefit from additional
treatment. Selective TCD guided administration of
Dextran has already been shown successful in reduc-
ing embolization and progression to stroke.13,20 How-
ever, this policy is expensive and labour intensive and
is unlikely to be adopted into routine clinical practice.
It would be preferable to target appropriate antiplate-
let pharmacotherapy from the outset.
In the present study we compared three different
perioperative antiplatelet regimens and their influ-
ence on clinical outcome and postoperative TCD
detected embolization in patients undergoing CEA.
Methods
Study design
The present randomized and double blinded pilot
study with 30 patients planned in each subgroup
was performed between 2004 and 2006 in the St.
Antonius Hospital, Nieuwegein, with Ethics Commit-
tee approval. All patients gave Informed Consent. In-
clusion criteria were 1) internal carotid artery (ICA)
stenosis of 70% on preoperative duplex ultrasound;
2) no preceding ipsilateral carotid intervention; 3)
accessible transcranial window for TCD registration.
Patients already on warfarin, dipyramidole, or Clopi-
dogrel were excluded. Patients were defined asymp-
tomatic in absence of cerebrovascular symptoms
within 120 days prior to surgery.
Carotid endarterectomy
Patients underwent standard CEA under general an-
aesthesia. Surgery was executed by an experienced
vascular surgeon or a vascular trainee under super-
vision. A shunt or patch was selectively used.
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Continuous TCD monitoring of the ipsilateral MCA for
the occurrence of MES was performed during opera-
tion and during the second hour postoperatively.
Four successive stages of operation were: 1) dissection
(skin preparation to carotid clamping; 2) shunt manip-
ulation (shunt introduction to shunt removal); 3) clamp
release; and 4) wound closure.21 All TCD data were
stored on CD Rom for offline analysis. Technical details
of intraoperative22 and postoperative23 monitoring
have been described previously. Postoperative emboli-
zation was quantified using standardized consensus
criteria.23,24 All TCD measurements were performed
by a single highly experienced technician (MvdM).
High grade postoperative embolization was defined
as >20 MES per hour.
Trial medication
Three different antiplatelet regimens (APT) were
compared in patients undergoing CEA.
Group I Asasantin 25/200 mg (dipyridamol 200 mg/
aspirin 25 mg) 2dd orally. Started at least
3 days preoperative and continued for
3 months postoperative.
Group II As group I but with addition of Clopidog-
rel 1dd 75 mg; started at least 3 days pre-
operative and also continued for 3 months
postoperative.
Group III As group I with addition of Rheomacrodex
(Dextran 40) solution 100 g/L iv; 500 ml
during the first 6 postoperative hours start-
ing during skin closure.
In all patients, heparin (5.000 IU) was administered
before cross-clamping; protamine reversal was not
used. Platelet aggregation tests were not performed.
Trial medication was blinded for both the surgeon
and TCD technician. Analysis of CD-rom stored
TCD data was performed on distance by T.H. and
R.A. who were also blinded for trial medication. Hep-
arin dose-response relationship was calculated with
the activated clotting time (ACT).
Study outcome
Primary outcomes were the number of postoperative
MES and the occurrence of adverse clinical
137A Prospective Randomised Trialneurological symptoms. Secondary outcome was the
occurrence of any bleeding complication. Before and af-
ter surgery, patients were evaluated by an independent
neurologist. Any new neurological deficit lasting for
>24 hours in the first 30 days was classified as a stroke.
The severity of stroke was graded according to the
modified Rankin scale.23 Intraoperative stroke was de-
fined as a persistent neurological deficit that became
obvious at the conclusion of the operation, or at awak-
ening from general anaesthesia. Postoperative stroke
was defined as a persistent neurological deficit that de-
veloped within 48 hours after a symptom free interval.
Group size
Power calculations could not be performed. The pres-
ent study was therefore a pilot with 30 patients
planned in each subgroup.
Protocol intervention
Patients were operated on with intention to treat. Pro-
tocol intervention was defined as any reoperation or
change in trial medication. Change of antiplatelet
medication after the initial monitoring hour (second
postoperative hour) was not considered to interfere
with protocol. Any patient suffering high grade post-
operative embolization was started on Rheomacrodex
according to hospital protocol.20 In these cases, TCD
registration was prolonged for 1 extra hour to monitor
the effect of drug intervention.
Statistical analysis
Data were analyzed using SPSS version 11.5 (SPSS Inc.
Chicago, Illinois). Groups were compared with
Students-T and chi-square test, or Mann-Whitney/
Kruskal-Wallis (K-W) tests for non-normally distrib-
uted variables. Correlations were tested using Pearson
correlation coefficient, or Spearman/Kendall (S/K)
for non-normally distributed data. Probability values
p> 0.05 were considered non-significant. To obtain
a normal distribution, and for display purposes,
a square root (sqrt) transformation of the number of
emboli was employed.
Results
Demographics
We included 102 patients (76 male mean age 67.5;
sd¼ 7.9, and 26 women mean age 64.7; sd¼ 10.1( p¼ 0.21)). In 53 patients (52%) the operation was per-
formed on the right side. Seventy-nine patients
(77.5%) were symptomatic (amaurosis fugax (AF)
9 (8.8%), transient ischaemic attack (TIA) 34 (33.3%),
minor stroke 32 (31.4%), and vertebro basilar insuffi-
ciency (VBI) 4 (3.9%). A shunt was used in
27 (36.3%) and a patch in 80 procedures (venous
47 (46%), Dacron 33 (32%)). All groups were well
matched, with no significant difference in age, sex,
weight, atherosclerotic risk factors, or presenting
symptom.
Trial medication
Allocation of trial medication: Group I (Asasantin): 39
(38.2%), Group II (Asa/Plavix) 33 (32.4%), Group III
(Asa/Rheo) 30 (29.4%). The allocation of men and
women in medication groups was statistically not dif-
ferent (Chi2) (Table 1). There was also no statistical
significant difference in medication group allocation
between the various clinical groups (Chi2) (Table 2).
TCD registered micro-embolization
There was no correlation between the number of
intraoperative MES during the 4 different operative
phases (S/K correlation). The number of intraopera-
tive emboli showed no difference between men and
women (Mann-Whitney U test). There was no correla-
tion between the intra- and postoperative MES
(S/K coefficient: NS) (Fig. 1). Interestingly, only the
number of emboli during woundclosure showed a
correlation with postoperative MES (S/K r¼ 0.26/
0.20, p¼ 0.008/0.011) (Fig. 2).
The total number of postoperative emboli in the
second postoperative hour showed a wide range of
variation (Table 3); and therefore a skewed distribu-
tion pattern (Fig. 3). Even after Sqrt (x) transformation
the population mean was influenced by high individ-
ual outliers (Fig. 4). However, different approaches of
analysis all showed a gradual decrease of MES in the
second postoperative hour (Fig. 5). This effect was
seen throughout the spectrum from low- to high-
grade embolization. Women showed significantly
more postoperative emboli than men. There was no
significant correlation between the side of surgery
Table 1. Allocation of men and women in 3 medication groups
Inclusion group
Asasantin Asa/Plavix Asa/Rheo
Sex Male 27 24 25
Female 12 9 5
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138 G. J. de Borst et al.( p¼ 0.75), the use of patch nor type of patch ( p¼ 0.89)
and/or shunt and the occurrence of postoperative
embolization.
There was no significant difference between the
number of postoperative emboli and different antipla-
telet regimens (Kruskal-Wallis test) (Figs. 6, 7).
Sub-analyses on sex, patients with 1 emboli, or
only patients >20 emboli/hour also did not reach
statistical significance.
Besides group III patients, another 8 patients (5M,
3F) required Rheomacrodex to control continued
embolization (Group I (4) and Group II (4)). In all 8
patients Rheomacrodex successfully decreased the
embolic rate, and no other adverse cerebral events
occurred in these 8 patients. None of these patients
was indicated for re-exploration.
Clinical outcome
No major strokes or deaths occurred. Adverse cere-
bral events occurred in 3 patients (3%). Two patients
Table 2. Allocation of preoperative symptoms to treatment groups
Inclusion group Total
Asasantin Asa/
Plavix
Asa/
Rheo
Symptomatology Asympt 11 7 5 23
TIA 9 14 11 34
Minor Stroke 14 6 12 32
AF 5 3 1 9
Other 0 3 1 4
Total 39 33 30 102
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Fig. 1. Correlation of intra- and post-operative embolization.
Non-parametric correlation: Spearman/Kendall correlation
coefficients: non significant. (Total number of emboli during
second postoperative hour versus Total number of emboli
during carotid endarterectomy).Eur J Vasc Endovasc Surg Vol 34, August 2007showed an intraoperative ipsilateral TIA (1 group II,
1 group III). In 1 patient an ipsilateral postoperative
minor stroke was observed (group I). With this com-
plication rate our study was underpowered to analyse
a relationship between adverse cerebral events and
APT. The patient with minor stroke had no preceding
high-rate embolization. Five patients received re-
exploration, all because of bleeding complication
(NS) (Table 4).
Discussion
In the present pilot study, we could not show a signif-
icant influence of different antiplatelet regimens on
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Fig. 2. Correlation of intraoperative parameters with post-
operative embolization.(Blue¼ closure of the arteriotomy,
green¼ restoration of circulation, red¼ dissection). (Post-
operative number of emboli vs perioperative emboli).
Only the number of emboli during woundclosure showed
some correlation with the postoperative number of emboli
(S/K r 0.26/0.20, p¼ 0.008/0.011).
Table 3. Total number of TCD detected emboli in complete study
group during the second postoperative hour (N[ 102)
N Valid 102
Missing 0
Mean 20.29
Median 5.00
Std. Deviation 49.693
Range 354
Minimum 0
Maximum 354
Percentiles 25 1.00
50 5.00
75 15.00
80 19.20
90 47.40
139A Prospective Randomised TrialTCD detected postoperative embolization following
CEA. In all 3 treatment sub-groups a gradual decrease
of emboli in the second postoperative hour was
shown. Women showed significantly more postopera-
tive emboli than men, but there was no significant
difference between sex and emboli in relation to
APT. Two intraoperative TIA’s and 1 postoperative
minor stroke were noted. Eight patients required
TCD directed Rheomacrodex to control continued
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Fig. 4. Total number of TCD detected emboli during the
second postoperative hour after transformation. (Frequency
vs Sqrt total number of emboli). Outliers are marked with an
arrow.
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Fig. 3. Total number of TCD detected emboli during the
second postoperative hour. (Frequency vs total number of
emboli).embolization, which showed to be successful in low-
ering the embolic rate in all 8.
Postoperative stroke was previously assumed to
follow technical error. However, in patients re-
explored for postoperative cerebral deficit, a platelet-
rich thrombus was invariably found adherent to
an otherwise normal endarterectomy zone.7,23,25
This suggested that it might be the patients’ inherent
platelet activity that determined those at risk of post-
operative thrombotic stroke, and not technical error.25
CEA involves the removal of atherosclerotic plaque
with resulting exposure of a relatively large area of
4e quarter3e quarter2e quarter1e quarter
G
e
o
m
e
t
r
i
c
 
M
e
a
n
 
(
+
/
-
 
S
E
)
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Fig. 5. Total number of TCD detected emboli durin the sec-
ond postoperative hour. Data for complete study group after
transformation, after splitting up for the separate quarters.
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Fig. 6. Postoperative number of TCD detected emboli for
complete study group after splitting up for different medi-
cation sub-groups. (Red¼ first quarter, green¼ second
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140 G. J. de Borst et al.underlying medial collagen and adventitia. This in-
jury to the arterial wall leads to platelet adherence
on the denuded vessel immediately after CEA in hu-
mans.26 The thrombogenic endarterectomy zone can
subsequently become the source of emboli following
flow restoration.
Stroke due to post-operative carotid thrombosis
(POCT) still complicates 2e3% of CEA’s and has
long been thought to be unpreventable. With the
evidence of increasing postoperative embolisation
preceding any neurological deficit4,8e13 this view has
changed. These TCD detected MES can serve as
a marker of stroke risk and as a surrogate marker
to evaluate and monitor antiplatelet agents.8,10,11
Administration of Dextran has been shown to both
reduce high-grade postoperative embolization and
prevent thromboembolic stroke, providing further ev-
idence of the important association between these two
events.4,13,20 Following the introduction of TCD-
directed Dextran therapy, the rate of thrombotic
stroke after CEA was shown to fall from 2.7 per cent
to zero.4,27 Although several authors have proposed
a threshold of MES for increased risk of adverse cere-
bral events,4,10,12,13,28 their outcome was highly
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Fig. 7. Postoperative number of TCD detected emboli for pa-
tients with 1 emboli, after splitting up for different medi-
cation sub-groups. (Red¼ first quarter, green¼ second
quarter, blue¼ third quarter, pink¼ fourth quarter).
Table 4. Bleeding complications in the three medication groups
Group I Group II Group II
Variable Asasantin
(n¼ 39)
Clopidogrel
(n¼ 33)
Rheomacrodex
(n¼ 30)
p
Transfusion 1 1 0 NS
Reexploration 1 2 2 NSEur J Vasc Endovasc Surg Vol 34, August 2007variable and thus at present no consensus exists on
which threshold to use.
Several hours of postoperative TCD monitoring is
impractical outside a research programme; however,
the technique appears to work in smaller periods
without loss of clinical yield.23 In our previous work
one hour monitoring appeared to be effective to select
patients in whom the number of microemboli did not
spontaneously decrease.23 In the present study, pa-
tients thus underwent 1-hour of monitoring which
had a sufficiently alarming function, since in 8 pa-
tients with sustained embolization (range 49e354/
hour; mean 149/hour) Rheomacrodex was successful
in lowering the embolic rate, and none of these 8 de-
veloped adverse cerebral events after leaving the
recovery room. These 8 patients should be considered
as failures within their own APT group (4 group I, 4
group II). Unfortunately, retrospectively, we found
no relation between embolization during wound-
closure (0 emboli (5), 1 emboli (2), 2 emboli (1)) and de-
velopment of high-grade postoperative embolization.
Identification of embolization during woundclosure
therefore does not seem to be helpful in selecting
patients who need pharmacological intervention.
Targeted modification of pre-operative APT will
probably be a promising alternative way in the pre-
vention of perioperative MES and subsequent devas-
tating cerebral events. Ideally, a ‘‘one-size-fits-all’’
APT could be designed. It is important to note that
commonly used pretreatment regimens with antipla-
telet agents, in most cases aspirin, do not abolish
thrombo-embolization in the early postoperative pe-
riod.17 Aspirin inhibits only 1 of the several pathways
of platelet activation, and platelet activation through
an aspirin insensitive pathway may be more impor-
tant in the occurrence of thrombo-embolization. Fur-
thermore, a significant proportion of patients taking
aspirin do not show laboratory evidence of platelet
inhibition18 although resistance to other antiplatelet
regimens also must be considered.
Dual therapy with aspirin may prove more ef-
fective in reducing thrombo-embolic complica-
tions.15,19,29 Ex-vivo experiments have confirmed the
synergistic antithrombotic effects of a combined ther-
apy and showed the early benefit obtained with
a loading dose of Clopidogrel.15 Hayes et al. have
also shown that in CEA patients, the preoperative re-
sponse of platelets to adenosine diphosphate (ADP)
was predictive of postoperative embolization, con-
cluding that platelet ADP-receptor antagonism could
prevent perioperative cerebral embolization.16 More
recent evidence showed a significant reduction in
postoperative embolization by the administration of
a single 75 mg dose of Clopidogrel the night prior to
141A Prospective Randomised Trial
Eur J Vasc Endovasc Surg Vol 34, August 2007surgery (in addition to regular aspirin).19 Clopidogrel
also showed significant reduction in expression of
markers of platelet activation in response to ADP
compared to aspirin or aspirin with dipyridamole.30
Clopidogrel therefore seems more efficacious than
other APTs at a molecular level but its clinical role re-
mains controversial.4 In our study, the number of
postoperative MES was lower in the Clopidogrel
group compared to group I and III but this difference
was not statistically significant (Fig. 6). When compar-
ing patients with 1 emboli, the number of emboli
was even higher in the group of patients receiving
Clopidogrel, but also this effect was not statistically
significant (Fig. 7).
In vivo, combined therapy with Clopidogrel and
aspirin significantly increased the bleeding time.31 In
our study, re-explorations were performed in 5 pa-
tients for bleeding complications which is in excess
of expectations following CEA. APT groups were
too small to find a relationship between bleeding com-
plication and APT (Table 4). Therefore, future studies
have to search for APT that balance between minimal
embolization rate and minimum of bleeding compli-
cations. In particular we need to know: 1) are certain
patients at increased risk of postoperative emboliza-
tion and thrombosis, and if so how can we identify
them?; 2) what is the best treatment for patients
with sustained embolization?; 3) what is the optimal
preoperative APT in lowering both postoperative
MES and adverse cerebral deficit?
The correlation of microemboli during wound clo-
sure with ongoing postoperative embolization is path-
ophysiologically interesting and theoretically of help
in identifying patients at risk for sustained emboliza-
tion.14 However, as described above, our 8 patients
that were provided additional Rheomacrodex hardly
showed embolization during woundclosure. Stork
et al. identified 3 factors associated with postoperative
MES: female sex, left-sided CEA, and absence of pre-
operative APT.14 Two of these are non-modifiable risk
factors, leaving only preoperative APT as a modifiable
factor influencing outcome.
Our study has several potential limitations. First,
>60 minutes monitoring might be needed to identify
differences in embolic rate. Second, it is important to
note that the analysis reported here was a pilot with
small group size. The study may therefore have
been underpowered. Third, plaque characteristics
were not studied in the present population. Fourth,
aggregation tests were not performed, but heparin
effect was checked by ACT. Based on ACT measure-
ments, no additional heparin was provided in this
study population. Fifth, a surrogate (MES) served as
a marker for clinical outcome (stroke). We believe
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utcome following CEA.4,27 However, it is harder to
how that the desired outcome (reduced thromboem-
olic stroke incidence) is based on the drug effect on
he surrogate. Although the dramatic reduction in em-
olic events in patients treated with Dextran or Rheo-
acrodex is encouraging, the fact that one of our
atients without warning signals on TCD still experi-
nced postoperative minor stroke is discouraging.
Despite, inhibiting postoperative embolization
eems to represent a therapeutic strategy in reducing
troke after CEA. Nevertheless, the role and clinical
fficacy of TCD detected microemboli as a surrogate
easure for stroke after CEA remains to be better val-
dated. First, further well-powered studies need to be
ndertaken to determine the optimum perioperative
PT in reducing postoperative embolization. Future
esearch has to focus on potentially more effective
ombinations of ASA with other antiplatelet drugs.
lthough TCD may still be used to identify patients
t high risk in the early postoperative period, it seems
ikely that the optimal role for TCD will be to develop
ovel targeted modification of pre-operative APT, so
hat, ultimately, no postoperative monitoring is neces-
ary at all.
Conclusion
n the present study no significant difference between
he number of postoperative emboli and different
ntiplatelet regimens was found. In all study sub-
roups, linear regression of emboli in the second
ostoperative hour was observed. TCD directed
heomacrodex infusion showed successful in lower-
ng MES rate.
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